Tema Etfs LLC Takes $1.07 Million Position in Immunome, Inc. $IMNM

Tema Etfs LLC acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 115,431 shares of the company’s stock, valued at approximately $1,074,000. Tema Etfs LLC owned about 0.13% of Immunome at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of IMNM. T. Rowe Price Investment Management Inc. increased its holdings in Immunome by 37.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after buying an additional 2,054,640 shares during the last quarter. Redmile Group LLC lifted its holdings in Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock worth $36,081,000 after buying an additional 533,161 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Immunome by 43.4% during the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock worth $28,987,000 after acquiring an additional 1,303,753 shares in the last quarter. EcoR1 Capital LLC increased its holdings in shares of Immunome by 5.2% in the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock valued at $27,454,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Primecap Management Co. CA increased its holdings in shares of Immunome by 1,115.7% in the 1st quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company’s stock valued at $22,974,000 after acquiring an additional 3,132,900 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Ratings Changes

IMNM has been the topic of several recent analyst reports. Evercore ISI initiated coverage on shares of Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. lowered their target price on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and set a $21.00 price target on shares of Immunome in a research note on Friday, November 7th. Finally, Craig Hallum assumed coverage on shares of Immunome in a research report on Friday, September 5th. They issued a “buy” rating and a $26.00 price target for the company. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immunome presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Immunome Trading Up 3.7%

IMNM stock opened at $20.09 on Friday. The company has a market capitalization of $1.84 billion, a P/E ratio of -6.81 and a beta of 2.17. The business has a 50 day simple moving average of $15.98 and a 200-day simple moving average of $11.77. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $20.40.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Research analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.